The drug is indicated for the treatment of dementia of the Alzheimer’s type
Lupin has received final approval for its donepezil hydrochloride tablets, 23 mg from the United States Food and Drug Administration (FDA) to market a generic version of Eisai’s Aricept, tablets, 23mg. Lupin’s US subsidiary, Lupin Pharmaceuticals Inc would commence promoting the product shortly in the US.
Lupin’s donepezil hydrochloride tablets, 23 mg are the AB rated generic equivalent of Eisai’s Aricept, tablets, 23mg and is indicated for the treatment of dementia of the Alzheimer’s type. Aricept, had US sales of $52.3 million.
Comments are closed.